321 related articles for article (PubMed ID: 21649578)
1. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.
Shuttleworth SJ; Silva FA; Cecil AR; Tomassi CD; Hill TJ; Raynaud FI; Clarke PA; Workman P
Curr Med Chem; 2011; 18(18):2686-714. PubMed ID: 21649578
[TBL] [Abstract][Full Text] [Related]
2. Present and future of PI3K pathway inhibition in cancer: perspectives and limitations.
Ciraolo E; Morello F; Hirsch E
Curr Med Chem; 2011; 18(18):2674-85. PubMed ID: 21649577
[TBL] [Abstract][Full Text] [Related]
3. Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.
Perry MWD; Abdulai R; Mogemark M; Petersen J; Thomas MJ; Valastro B; Westin Eriksson A
J Med Chem; 2019 May; 62(10):4783-4814. PubMed ID: 30582813
[TBL] [Abstract][Full Text] [Related]
4. Isoform-Selective PI3K Inhibitors for Various Diseases.
Bheemanaboina RRY
Curr Top Med Chem; 2020; 20(12):1074-1092. PubMed ID: 31903879
[TBL] [Abstract][Full Text] [Related]
5. The PI3K inhibitor arsenal: choose your weapon!
Crabbe T; Welham MJ; Ward SG
Trends Biochem Sci; 2007 Oct; 32(10):450-6. PubMed ID: 17920279
[TBL] [Abstract][Full Text] [Related]
6. Phosphoinositide 3-kinase pathway inhibitors: pharmacology, metabolism & drug development.
Falasca M
Curr Med Chem; 2011; 18(18):2673. PubMed ID: 21649576
[No Abstract] [Full Text] [Related]
7. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.
Akinleye A; Avvaru P; Furqan M; Song Y; Liu D
J Hematol Oncol; 2013 Nov; 6(1):88. PubMed ID: 24261963
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of phosphoinositide 3-kinase inhibitors.
Ward S; Sotsios Y; Dowden J; Bruce I; Finan P
Chem Biol; 2003 Mar; 10(3):207-13. PubMed ID: 12670534
[TBL] [Abstract][Full Text] [Related]
9. Drugging the PI3 kinome: from chemical tools to drugs in the clinic.
Workman P; Clarke PA; Raynaud FI; van Montfort RL
Cancer Res; 2010 Mar; 70(6):2146-57. PubMed ID: 20179189
[TBL] [Abstract][Full Text] [Related]
10. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.
Liu Y; Wan WZ; Li Y; Zhou GL; Liu XG
Oncotarget; 2017 Jan; 8(4):7181-7200. PubMed ID: 27769061
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic applications of PI3K inhibitors in cardiovascular diseases.
Ghigo A; Morello F; Perino A; Hirsch E
Future Med Chem; 2013 Mar; 5(4):479-92. PubMed ID: 23495693
[TBL] [Abstract][Full Text] [Related]
12. Targeting phosphoinositide 3-kinase gamma to fight inflammation and more.
Barberis L; Hirsch E
Thromb Haemost; 2008 Feb; 99(2):279-85. PubMed ID: 18278175
[TBL] [Abstract][Full Text] [Related]
13. Functional redundancy of class I phosphoinositide 3-kinase (PI3K) isoforms in signaling growth factor-mediated human neutrophil survival.
Juss JK; Hayhoe RP; Owen CE; Bruce I; Walmsley SR; Cowburn AS; Kulkarni S; Boyle KB; Stephens L; Hawkins PT; Chilvers ER; Condliffe AM
PLoS One; 2012; 7(9):e45933. PubMed ID: 23029326
[TBL] [Abstract][Full Text] [Related]
14. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase.
Bago R; Malik N; Munson MJ; Prescott AR; Davies P; Sommer E; Shpiro N; Ward R; Cross D; Ganley IG; Alessi DR
Biochem J; 2014 Nov; 463(3):413-27. PubMed ID: 25177796
[TBL] [Abstract][Full Text] [Related]
15. Drugging PI3K in cancer: refining targets and therapeutic strategies.
Yap TA; Bjerke L; Clarke PA; Workman P
Curr Opin Pharmacol; 2015 Aug; 23():98-107. PubMed ID: 26117819
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibitors: facing new challenges ahead.
Mavrommati I; Maffucci T
Curr Med Chem; 2011; 18(18):2743-62. PubMed ID: 21649581
[TBL] [Abstract][Full Text] [Related]
17. Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective.
Garces AE; Stocks MJ
J Med Chem; 2019 May; 62(10):4815-4850. PubMed ID: 30582807
[TBL] [Abstract][Full Text] [Related]
18. Involvement of autophagy in the response of tumor cells to PtdIns3K inhibitors: therapeutic implications.
Arcaro A
Autophagy; 2013 Apr; 9(4):607-8. PubMed ID: 23324613
[TBL] [Abstract][Full Text] [Related]
19. Targeting PI3K signaling in cancer: Challenges and advances.
De Santis MC; Gulluni F; Campa CC; Martini M; Hirsch E
Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):361-366. PubMed ID: 30946868
[TBL] [Abstract][Full Text] [Related]
20. PI3K class IB pathway.
Andrews S; Stephens LR; Hawkins PT
Sci STKE; 2007 Oct; 2007(407):cm2. PubMed ID: 17925573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
